The Application of Clinical Genetics Dovepress Inherited and Acquired Alterations in Development of Breast Cancer

Breast cancer is the most common cancer among women, accounting for about 30% of all cancers. In contrast, breast cancer is a rare disease in men, accounting for less than 1% of all cancers. Up to 10% of all breast cancers are hereditary forms, caused by inherited germ-line mutations in " high-penetrance, " " moderate-penetrance, " and " low-penetrance " breast cancer susceptibility genes. The remaining 90% of breast cancers are due to acquired somatic genetic and epigenetic alterations. A heterogeneous set of somatic alterations, including mutations and gene amplification, are reported to be involved in the etiology of breast cancer. Promoter hypermethylation of genes involved in DNA repair and hormone-mediated cell signaling, as well as altered expression of micro RNAs predicted to regulate key breast cancer genes, play an equally important role as genetic factors in development of breast cancer. Elucidation of the inherited and acquired genetic and epigenetic alterations involved in breast cancer may not only clarify molecular pathways involved in the development and progression of breast cancer itself, but may also have an important clinical and therapeutic impact on improving the management of patients with the disease.

[1]  C. Atalay Epigenetics in breast cancer. , 2013, Experimental oncology.

[2]  R. Saxena,et al.  ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective , 2012, Medicinal research reviews.

[3]  H. Meijers-Heijboer,et al.  PALB2 analysis in BRCA2-like families , 2011, Breast Cancer Research and Treatment.

[4]  C. Croce,et al.  MicroRNAs as therapeutic targets in cancer. , 2011, Translational research : the journal of laboratory and clinical medicine.

[5]  S. Bianchi,et al.  Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in Central Italy , 2011, Breast Cancer Research and Treatment.

[6]  S. Neuhausen,et al.  Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States , 2011, Breast Cancer Research and Treatment.

[7]  D. Palli,et al.  Mutation screening of RAD51C in male breast cancer patients , 2011, Breast Cancer Research.

[8]  Andreas Rimner,et al.  MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. , 2011, Genes & development.

[9]  E. John,et al.  Germline mutations in PALB2 in African-American breast cancer cases , 2011, Breast Cancer Research and Treatment.

[10]  J. Dopazo,et al.  Exploring the Link between Germline and Somatic Genetic Alterations in Breast Carcinogenesis , 2010, PloS one.

[11]  Jonathan W. Pillow,et al.  POSTER PRESENTATION Open Access , 2013 .

[12]  L. Ottini,et al.  HER2-positive male breast cancer: an update. , 2010, Breast cancer.

[13]  P. Watson,et al.  Alternative Splicing in Prostate and Breast Cancer , 2010 .

[14]  E. Sensi,et al.  PALB2: a novel inactivating mutation in a Italian breast cancer family , 2010, Familial Cancer.

[15]  M. Nóbrega,et al.  An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer. , 2010, Genome research.

[16]  Marc Tischkowitz,et al.  RAD51C germline mutations in breast and ovarian cancer patients , 2010, Breast Cancer Research.

[17]  Jing Zhang,et al.  Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer , 2010, Breast Cancer Research and Treatment.

[18]  Deborah Hughes,et al.  Genome-wide association study identifies five new breast cancer susceptibility loci , 2010, Nature Genetics.

[19]  F. Sera,et al.  A PALB2 germline mutation associated with hereditary breast cancer in Italy , 2010, Familial Cancer.

[20]  Dieter Niederacher,et al.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene , 2010, Nature Genetics.

[21]  Olivia Fletcher,et al.  Architecture of inherited susceptibility to common cancer , 2010, Nature Reviews Cancer.

[22]  E. Levy-Lahad,et al.  Fanconi anemia and breast cancer susceptibility meet again , 2010, Nature Genetics.

[23]  Daniel J. Park,et al.  Are PALB2 mutations associated with increased risk of male breast cancer? , 2010, Breast Cancer Research and Treatment.

[24]  M. Troxell,et al.  Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma , 2010, Breast Cancer Research and Treatment.

[25]  Thomas Streichert,et al.  Identification of differentially expressed microRNAs in human male breast cancer , 2010, BMC Cancer.

[26]  S. Bianchi,et al.  PALB2 mutations in male breast cancer: a population-based study in Central Italy , 2010, Breast Cancer Research and Treatment.

[27]  Lei Yao,et al.  BRCA2 N372H polymorphism and breast cancer susceptibility: a meta-analysis involving 44,903 subjects , 2010, Breast Cancer Research and Treatment.

[28]  M. Dąbrowska,et al.  A novel germline PALB2 deletion in Polish breast and ovarian cancer patients , 2010, BMC Medical Genetics.

[29]  A. Levine,et al.  Germline Mutations and Polymorphisms in the Origins of Cancers in Women , 2010, Journal of oncology.

[30]  A. Børresen-Dale,et al.  COMPLEX LANDSCAPES OF SOMATIC REARRANGEMENT IN HUMAN BREAST CANCER GENOMES , 2009, Nature.

[31]  Philip S Rosenberg,et al.  Male breast cancer: a population-based comparison with female breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Shenouda,et al.  MicroRNA function in cancer: oncogene or a tumor suppressor? , 2009, Cancer and Metastasis Reviews.

[33]  D. Bell Our changing view of the genomic landscape of cancer , 2009, The Journal of pathology.

[34]  C. Croce Causes and consequences of microRNA dysregulation in cancer , 2009, Nature Reviews Genetics.

[35]  F. Sera,et al.  Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy , 2009, Breast Cancer Research and Treatment.

[36]  Stefano Volinia,et al.  MicroRNA expression profiling of male breast cancer , 2009, Breast Cancer Research.

[37]  F. Sera,et al.  BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy , 2009, Breast Cancer Research and Treatment.

[38]  N. Guo,et al.  MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. , 2009, Cancer treatment reviews.

[39]  A. Toland,et al.  Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. , 2009, Seminars in cancer biology.

[40]  W. Willett,et al.  A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1) , 2009, Nature Genetics.

[41]  H. Nevanlinna,et al.  The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor Phenotype , 2009, Clinical Cancer Research.

[42]  Z. Shao,et al.  Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives , 2009, Breast Cancer Research and Treatment.

[43]  Anders Albrechtsen,et al.  Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families , 2009, Breast Cancer Research and Treatment.

[44]  P. Nederlof,et al.  High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. , 2009, Cancer research.

[45]  S. Michiels,et al.  Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. , 2009, The Lancet. Oncology.

[46]  Z. Shao,et al.  The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives , 2009, Breast Cancer Research and Treatment.

[47]  E. V. Rensburg,et al.  PALB2 sequence variants in young South African breast cancer patients , 2009, Familial Cancer.

[48]  Julian Peto,et al.  Association of ESR1 gene tagging SNPs with breast cancer risk. , 2009, Human molecular genetics.

[49]  J. Lubiński,et al.  Genetic heterogeneity of 8q24 region in susceptibility to cancer. , 2009, Journal of the National Cancer Institute.

[50]  M. Urioste,et al.  Analysis of FANCB and FANCN/PALB2 Fanconi Anemia genes in BRCA1/2-negative Spanish breast cancer families , 2009, Breast Cancer Research and Treatment.

[51]  S. Chanock,et al.  Genetic Susceptibility Loci for Breast Cancer by Estrogen Receptor Status , 2008, Clinical Cancer Research.

[52]  A. Jakubowska,et al.  A range of cancers is associated with the rs6983267 marker on chromosome 8. , 2008, Cancer research.

[53]  Yong-Yeon Cho,et al.  Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells , 2008, Breast Cancer Research.

[54]  Sherif Abou Elela,et al.  Identification of alternative splicing markers for breast cancer. , 2008, Cancer research.

[55]  Qiong Shao,et al.  MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. , 2008, RNA.

[56]  H. Sasaki,et al.  Bmc Cancer , 2008 .

[57]  Olufunmilayo I Olopade,et al.  MYC in breast tumor progression , 2008, Expert review of anticancer therapy.

[58]  J. Reis-Filho,et al.  Hereditary breast cancer: from molecular pathology to tailored therapies , 2008, Journal of Clinical Pathology.

[59]  John L Hopper,et al.  Multiple loci with different cancer specificities within the 8q24 gene desert. , 2008, Journal of the National Cancer Institute.

[60]  D. Palli,et al.  BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases , 2008, Breast Cancer Research and Treatment.

[61]  A. Sigurdsson,et al.  Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer , 2008, Nature Genetics.

[62]  Masaru Shinozaki,et al.  Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors , 2008, Breast Cancer Research.

[63]  J. Bartlett,et al.  Genetic alterations of CCND1 and EMSY in breast cancers , 2008, Histopathology.

[64]  J. Simard,et al.  Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families , 2008, Journal of Human Genetics.

[65]  Dieter Niederacher,et al.  Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. , 2008, American journal of human genetics.

[66]  Z. Kolár̂,et al.  The status and role of ErbB receptors in human cancer. , 2008, Experimental and molecular pathology.

[67]  D. Coradini,et al.  PIK3CA cancer mutations display gender and tissue specificity patterns , 2008, Human mutation.

[68]  S. Bojesen,et al.  CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Asli Silahtaroglu,et al.  Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. , 2007, Cancer research.

[70]  W. Foulkes,et al.  Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women , 2007, Breast Cancer Research.

[71]  P. Willems Susceptibility genes in breast cancer: more is less? , 2007 .

[72]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[73]  C. de Wolf‐Peeters,et al.  The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity , 2007, Current opinion in oncology.

[74]  Xin Hu,et al.  Correlation between CpG methylation profiles and hormone receptor status in breast cancers , 2007, Breast Cancer Research.

[75]  D. Gudbjartsson,et al.  Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor–positive breast cancer , 2007, Nature Genetics.

[76]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.

[77]  Hongjuan Zhao,et al.  TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer , 2007, Breast Cancer Research.

[78]  G. Sauter,et al.  Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer , 2007, Nature Genetics.

[79]  M. Tejada,et al.  Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer , 2007, Breast Cancer Research and Treatment.

[80]  M. Tejada,et al.  CHEK2 1100delC is present in familial breast cancer cases of the Basque Country , 2007, Breast Cancer Research and Treatment.

[81]  Petra M. Nederlof,et al.  Analysis of PALB2/FANCN-associated breast cancer families , 2007, Proceedings of the National Academy of Sciences.

[82]  M. Esteller Cancer epigenomics: DNA methylomes and histone-modification maps , 2007, Nature Reviews Genetics.

[83]  Katri Pylkäs,et al.  A recurrent mutation in PALB2 in Finnish cancer families , 2007, Nature.

[84]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[85]  Jaana M. Hartikainen,et al.  A common coding variant in CASP8 is associated with breast cancer risk , 2007, Nature Genetics.

[86]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[87]  A. Ghaderi,et al.  Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. , 2007, Cancer genetics and cytogenetics.

[88]  M. Monden,et al.  Clinicopathologic Analysis of Breast Cancers with PIK3CA Mutations in Japanese Women , 2007, Clinical Cancer Research.

[89]  A. Thompson,et al.  Cyclin D1 and breast cancer. , 2006, Breast.

[90]  Nazneen Rahman,et al.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles , 2006, Nature Genetics.

[91]  J. Soares,et al.  Evaluation of ERBB2 Gene Status and Chromosome 17 Anomalies in Male Breast Cancer , 2006, The American journal of surgical pathology.

[92]  G. Francis,et al.  Evaluation of oestrogen and progesterone receptor status in HER‐2 positive breast carcinomas and correlation with outcome , 2006, Pathology.

[93]  Nazneen Rahman,et al.  ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles , 2006, Nature Genetics.

[94]  B. Iacopetta,et al.  DNA hypermethylation in breast cancer and its association with clinicopathological features. , 2006, Cancer letters.

[95]  K. Edmiston,et al.  HER-2 Status in Breast Cancer: Correlation of Gene Amplification by FISH With Immunohistochemistry Expression Using Advanced Cellular Imaging System , 2006, Applied immunohistochemistry & molecular morphology : AIMM.

[96]  T. Walsh,et al.  Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. , 2006, JAMA.

[97]  M. Murphy,et al.  Polymorphisms in the p53 pathway , 2006, Oncogene.

[98]  M. Urioste,et al.  A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers , 2006, Human mutation.

[99]  M. Campiglio,et al.  Role of exon-16-deleted HER2 in breast carcinomas. , 2006, Endocrine-related cancer.

[100]  B. Iacopetta,et al.  PIK3CA mutations in breast cancer are associated with poor outcome , 2006, Breast Cancer Research and Treatment.

[101]  Leif E. Peterson,et al.  Characterization of BRCA1 and BRCA2 mutations in a large United States sample. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  A. Marchetti,et al.  PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma , 2006, The Journal of pathology.

[103]  S. Narod,et al.  CHEK2 mutation and hereditary breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  Li Zhao,et al.  Oncogenic PI3K deregulates transcription and translation , 2005, Nature Reviews Cancer.

[105]  A. Spurdle,et al.  Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer , 2005, Breast Cancer Research.

[106]  T. Dörk,et al.  Association of two mutations in the CHEK2 gene with breast cancer , 2005, International journal of cancer.

[107]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[108]  Lesley McGuffog,et al.  Cancer risks and mortality in heterozygous ATM mutation carriers. , 2005, Journal of the National Cancer Institute.

[109]  J. Kirk,et al.  Large genomic rearrangements of both BRCA2 and BRCA1 are a feature of the inherited breast/ovarian cancer phenotype in selected families , 2005, Journal of Medical Genetics.

[110]  Hanina Hibshoosh,et al.  PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.

[111]  Peter Schraml,et al.  Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer , 2004, Cancer Research.

[112]  P. Chappuis,et al.  Significant Contribution of Germline BRCA2 Rearrangements in Male Breast Cancer Families , 2004, Cancer Research.

[113]  Wayne A. Phillips,et al.  Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.

[114]  A. Auvinen,et al.  Frequent amplification and overexpression of CCND1 in male breast cancer , 2004, International journal of cancer.

[115]  J. Herman,et al.  Hypermethylation in Histologically Distinct Classes of Breast Cancer , 2004, Clinical Cancer Research.

[116]  Luke Hughes-Davies,et al.  Amplification of the BRCA2 Pathway Gene EMSY in Sporadic Breast Cancer Is Related to Negative Outcome , 2004, Clinical Cancer Research.

[117]  D. Seripa,et al.  Nonrandom Distribution of Aberrant Promoter Methylation of Cancer-Related Genes in Sporadic Breast Tumors , 2004, Clinical Cancer Research.

[118]  Douglas Easton,et al.  The Genetic Epidemiology of Breast Cancer Genes , 2004, Journal of Mammary Gland Biology and Neoplasia.

[119]  P. Radice,et al.  The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy , 2004, Human mutation.

[120]  Martin Widschwendter,et al.  Association of Breast Cancer DNA Methylation Profiles with Hormone Receptor Status and Response to Tamoxifen , 2004, Cancer Research.

[121]  Hiroyuki Konishi,et al.  The PIK3CA gene is mutated with high frequency in human breast cancers , 2004, Cancer biology & therapy.

[122]  A. Auvinen,et al.  CHEK2 1100delC is not a risk factor for male breast cancer population , 2004, International journal of cancer.

[123]  E. Friedman,et al.  CHEK2*1100delC and male breast cancer risk in Israel , 2004, International journal of cancer.

[124]  D. Easton,et al.  Role of CHEK2*1100delC in unselected series of non‐BRCA1/2 male breast cancers , 2004, International journal of cancer.

[125]  M. Fackler,et al.  DNA methylation of RASSF1A, HIN‐1, RAR‐β, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma , 2003, International journal of cancer.

[126]  E. Oláh,et al.  Emerging roles of BRCA1 alternative splicing , 2003, Molecular pathology : MP.

[127]  R. Wooster,et al.  Breast and ovarian cancer. , 2003, The New England journal of medicine.

[128]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[129]  T. Rebbeck,et al.  Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1? , 2003, Journal of Medical Genetics.

[130]  R. Winqvist,et al.  No evidence of involvement of germline BACH1 mutations in Finnish breast and ovarian cancer families. , 2003, European journal of cancer.

[131]  S. Narod,et al.  A low frequency of non‐founder BRCA1 mutations in Ashkenazi Jewish breast–ovarian cancer families , 2002, Human mutation.

[132]  R. Lidereau,et al.  Molecular alterations in sporadic breast cancer. , 2002, Critical reviews in oncology/hematology.

[133]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[134]  D. Easton,et al.  Variation in BRCA1 cancer risks by mutation position. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[135]  B. Ward,et al.  Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  Douglas F. Easton,et al.  Polygenic susceptibility to breast cancer and implications for prevention , 2002, Nature Genetics.

[137]  R. Delongchamp,et al.  Prospects for applying genotypic selection of somatic oncomutation to chemical risk assessment. , 2001, Mutation research.

[138]  M. Olivier,et al.  TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. , 2001, Seminars in cancer biology.

[139]  P. Radice,et al.  Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer , 2001, Human mutation.

[140]  L. Kadouri,et al.  A deletion/insertion mutation in the BRCA2 gene in a breast cancer family: A possible role of the Alu‐polyA tail in the evolution of the deletion , 2001, Genes, chromosomes & cancer.

[141]  S. Seal,et al.  Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  J. Kononen,et al.  Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. , 2000, Cancer research.

[143]  B. Weber,et al.  Genetic and hormonal risk factors in breast cancer. , 2000, Journal of the National Cancer Institute.

[144]  J. Ross,et al.  The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, The oncologist.

[145]  M. Hung,et al.  A novel splice variant of HER2 with increased transformation activity , 1998, Molecular carcinogenesis.

[146]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[147]  D. Clayton,et al.  Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. , 1997, Human molecular genetics.

[148]  M. Skolnick,et al.  BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations. , 1996, Oncogene.

[149]  R. Zeillinger,et al.  Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors , 1996, International journal of cancer.

[150]  D. Easton,et al.  High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. , 1996, Cancer research.

[151]  M. Skolnick,et al.  Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. , 1996, Human molecular genetics.

[152]  J. Eyfjörd,et al.  A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes , 1996, Nature Genetics.

[153]  S. Weitzman,et al.  Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[154]  J. Gudmundsson,et al.  Frequent occurrence of BRCA2 linkage in Icelandic breast cancer families and segregation of a common BRCA2 haplotype. , 1996, American journal of human genetics.

[155]  F. Collins,et al.  The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals , 1995, Nature Genetics.

[156]  S. Friend,et al.  Screening for germ line TP53 mutations in breast cancer patients. , 1992, Cancer research.

[157]  C. Harris,et al.  Oncogenes and tumor-suppressor genes. , 1991, Environmental health perspectives.

[158]  M. Swift,et al.  Breast and other cancers in families with ataxia-telangiectasia. , 1987, The New England journal of medicine.

[159]  S. Tommasi,et al.  Gene copy number variation in male breast cancer by aCGH , 2011, Cellular Oncology.

[160]  E. V. Rensburg,et al.  Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation , 2010, Breast Cancer Research and Treatment.

[161]  A. Russo,et al.  Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation? , 2008, Breast Cancer Research and Treatment.

[162]  Georgia Chenevix-Trench,et al.  Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumors , 2008, Breast Cancer Research and Treatment.

[163]  F. Liebens,et al.  Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. , 2007, European journal of cancer.

[164]  Nazneen Rahman,et al.  The emerging landscape of breast cancer susceptibility , 2007, Nature Genetics.

[165]  A. Kallioniemi,et al.  Large genomic BRCA2 rearrangements and male breast cancer. , 2006, Cancer detection and prevention.

[166]  A. P. Damin,et al.  Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. , 2006, Cancer detection and prevention.

[167]  Shih-Feng Tsai,et al.  Chromosomal comparative genomic hybridization abnormalities in early- and late-onset human breast cancers: correlation with disease progression and TP53 mutations. , 2004, Cancer genetics and cytogenetics.

[168]  S. Tsutsui,et al.  Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer , 2004, Breast Cancer Research and Treatment.

[169]  K. Shiraki,et al.  Breast cancer genetics: what we know and what we need , 2001, Nature Medicine.

[170]  A. Lindblom,et al.  A study of the PTEN/MMAC1 gene in 136 breast cancer families. , 1998, Human genetics.

[171]  R. Tuckuviene,et al.  submit your manuscript | www.dovepress.com , 2022 .